Overview

Glasdegib for Chronic Graft-Versus-Host Disease

Status:
Recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborators:

National Cancer Institute (NCI)
Pfizer